Document is current

Article History

Received: 8 August 2024

Accepted: 13 March 2025

First Online: 28 March 2025

Declarations

:

: The following ethics committees approved the experiments: Copernicus Group IRB, P.O. Box 110605, Research Triangle Park, NC 27709, approval given on May 27th 2016; Washington University in St. Louis, Human Protection Office, 660 South Euclid Ave., Campus Box 8089, St. Louis, MO 63110, approval given on 5th August 2016; Alpha IRB, 1001 Avenida Pico, Suite C#497, San Clemente, CA 92673, approval given on 8th July 2016; Integ Review IRB, 3815 S. Capital of Texas Hwy, Suite 320, Austin, TX 78704, approval given on 27th May 2016. Informed consent to participate in the study was obtained from all participants.

: Not applicable.

: Co-author D. Umbricht is owner of xperimed LLC that provides consultation on all aspects of clinical drug development for neuropsychiatric indications, works on a contracting basis for Autifony Therapeutics and Gilgamesh pharmaceuticals and holds stocks of Roche, Novartis and Gilgamesh Pharmaceuticals. He has been consulting to Abbvie, Biogen, ERG, Forbion, Healthrhyhms, Kynexis, Psychogenic, Roche and Siesta. Co-author D. Umbricht was a full-time employee of F. Hoffmann-La Roche Ltd., which held the license for RG7203 during the study period. Co-author Š. Holiga is a full-time employee of F. Hoffmann-La Roche Ltd. Co-author G. Garibaldi is the chief medical officer of Noema, which currently holds the license for RG7203, and advisor of Retrotope. P. Homan has received grants and honoraria from Novartis, Lundbeck, Mepha, Janssen, Boehringer Ingelheim, Neurolite outside of this work. No further disclosures were reported.